Ionis Pharmaceuticals, Inc.
2855 Gazelle Court
About Ionis Pharmaceuticals, Inc.
Ionis Pharmaceuticals, Inc., located in the North San Diego County city of Carlsbad, was founded in 1989 to create advanced, novel medicines to treat complex and challenging diseases. We are the pioneer in the discovery and development of antisense drugs with more than 1300 patents.
Ionis is a challenging, motivating and rewarding environment designed to foster innovation and scientific excellence. Our founding goals have changed little in over 27 years and our success is a direct result of our outstanding employees. We are interested in bringing together individuals with different skill sets into this creative environment to be part of a productive team. Join us and experience our unique culture while you develop and expand your career.
726 articles with Ionis Pharmaceuticals, Inc.
Ionis Pharmaceuticals, Inc. reported its financial results for the first quarter of 2019 and recent business highlights.
Ionis launches new corporate brand that reflects company's industry-leading innovation and unique culture of saying "yes" to patients
Ionis Pharmaceuticals, Inc. unveiled its new corporate brand in a campaign inspired by its unique culture and history of developing transformative therapies for seemingly untreatable diseases.
Positive clinical data at AAN 2019 reinforces Ionis' commitment to delivering life-changing medicines to patients with neurological diseases
Twelve presentations highlighting transformational medicines for SMA, hATTR, Huntington's disease, ALS, prion disease and others
Webcast scheduled for Thursday, May 9th at 11:30 a.m. Eastern Time
Ionis Pharmaceuticals, Inc. announced that management will present a general corporate update in conjunction with its 2019 Annual Meeting of Stockholders and Open House on Thursday, June 6 at 2:10 p.m. Pacific Time in Carlsbad, CA.
Ionis Pharmaceuticals, Inc., the leader in RNA-targeted therapeutics, announced that Brett P. Monia, Ph.D., has been appointed to the company's board of directors.
Biotech and pharma companies from across the globe share data and news in a weekly roundup.
PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced that its partner, Akcea Therapeutics, affiliate of Ionis Pharmaceuticals, received a positive opinion for WAYLIVRA™ by the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA
Akcea Therapeutics, Inc. (NASDAQ: AKCA), an affiliate of Ionis Pharmaceuticals, Inc., and Ionis Pharmaceuticals, Inc. (NASDAQ: IONS), announced today that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion recommending conditional marketing authorization for WAYLIVRA
Akcea® Recognizes Rare Disease Day Through Efforts to Increase Awareness of Hereditary Transthyretin Amyloidosis and Familial Chylomicronemia Syndrome
Akcea Therapeutics, Inc. (NASDAQ: AKCA), an affiliate of Ionis Pharmaceuticals, Inc., focused on developing and commercializing drugs to treat patients with serious and rare diseases, today announced the company’s support for Rare Disease Day 2019 for patients living with hereditary transthyretin (hATTR) amyloidosis and familial chylomicronemia syndrome (FCS) and their caregivers, including bringing several of them together to participate in a live panel discussion related to their disease.
Ionis Pharmaceuticals, Inc. reported financial results for the fourth quarter and full year 2018 and reviewed highlights of its successful year.
Akcea Therapeutics, Inc. (NASDAQ: AKCA), an affiliate of Ionis Pharmaceuticals, Inc., and Ionis Pharmaceuticals, Inc. (NASDAQ: IONS), today announced that Novartis has exercised its option to license AKCEA-APO(a)-LRx, a drug to treat patients with elevated levels of lipoprotein(a), or Lp(a), and established cardiovascular disease (CVD). AKCEA-APO(a)-LRx, referred to by Novartis as TQJ230, was discovered by Ionis and co-developed by Akcea and Ionis.
Ionis Pharmaceuticals, Inc. (NASDAQ: IONS) announced today that it will host a live webcast on Wednesday, February 27th at 11:30 a.m. Eastern Time to discuss its 2018 financial results and report on pipeline and business progress.
First Patient Enrolled in Pivotal Study of RG6042 (IONIS-HTT Rx) for People with Huntington's Disease
First of 4+ Ionis programs expected to advance to pivotal studies this year
Ionis Pharmaceuticals, Inc. today announced that Management will present a Company overview at the 37th Annual J.P. Morgan Healthcare Conference on Monday, January 7, 2019 at 4:00 p.m. PT in San Francisco, CA.
Ionis Pharmaceuticals, Inc. and its Board of Directors announced today that, effective January 2020, Ionis' founder and CEO, Stanley T. Crooke, M.D., Ph.D., will be transitioning from chief executive officer to executive chairman of Ionis' board of directors.
First-in-class therapies using advanced antisense chemistries highlighted at 2018 American Society of Hematology Annual Meeting
Wholly-owned LICA drug for beta-thalassemia, IONIS-TMPRSS6-L Rx, demonstrates therapeutic potential with positive modulation of important disease-related biomarkers and increase of serum hepcidin in initial clinical study
Ionis Pharmaceuticals, Inc. today announced that management will present a company overview at the Jefferies 2018 London Healthcare Conference.
Phase 2 Results on AKCEA-APO(a)-LRx Presented in Late-Breaking Clinical Trial Presentation at AHA Scientific Sessions
Akcea Therapeutics, Inc. (NASDAQ: AKCA), an affiliate of Ionis Pharmaceuticals, Inc., and Ionis Pharmaceuticals, Inc. (NASDAQ: IONS), today announced that data from the Phase 2 clinical study of AKCEA-APO(a)-LRx in patients with established cardiovascular disease (CVD) and elevated levels of lipoprotein(a), or Lp(a), were presented in a late-breaking clinical trial presentation at the American Heart Association Scientific Sessions in Chicago November 10, 2018.
Ionis Pharmaceuticals, Inc. (NASDAQ: IONS), the leader in antisense therapeutics, today announced that management will host an Investor Day on Friday, December 7th at 7:30 a.m. Eastern Time at Marriott East Side in New York, NY.